FDA Oxycodone Enforcement Built On Difference Between “Same” And “Identical”
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies must stop manufacturing unapproved single-ingredient, immediate-release oxycodone products in oral dosage forms within 45 days; FDA rejects Lannett petition, saying it has not provided evidence its oxycodone is identical to a pre-1938 product.